Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
[The active neuroprotective therapy of acute carotid ischemic stroke of moderate severity].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Kukhtevich II, Aleshina NI, Levashova OA.
PMID: 25726801
Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(12):38-42. doi: 10.17116/jnevro201411412238-42.

Objective. To evaluate the efficacy of neuroprotective therapy in carotid ischemic stroke. Material and methods. An open comparative study of combined neuroprotective therapy in comparison with standard treatment has been carried out in 25 patients with carotid ischemic stroke...

Cite
Kukhtevich II, Aleshina NI, Levashova OA. Aktivnaia neĭroprotektivnaia terapiia ostrogo karotidnogo ishemicheskogo insul'ta sredneĭ stepeni tiazhesti. [The active neuroprotective therapy of acute carotid ischemic stroke of moderate severity]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(12):38-42doi: 10.17116/jnevro201411412238-42.
Kukhtevich, I. I., Aleshina, N. I., & Levashova, O. A. (2014). Aktivnaia neĭroprotektivnaia terapiia ostrogo karotidnogo ishemicheskogo insul'ta sredneĭ stepeni tiazhesti. [The active neuroprotective therapy of acute carotid ischemic stroke of moderate severity]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 114(12), 38-42. https://doi.org/10.17116/jnevro201411412238-42
Kukhtevich, I I, et al. "Aktivnaia neĭroprotektivnaia terapiia ostrogo karotidnogo ishemicheskogo insul'ta sredneĭ stepeni tiazhesti." [The active neuroprotective therapy of acute carotid ischemic stroke of moderate severity]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova vol. 114,12 (2014): 38-42. doi: https://doi.org/10.17116/jnevro201411412238-42
Kukhtevich II, Aleshina NI, Levashova OA. Aktivnaia neĭroprotektivnaia terapiia ostrogo karotidnogo ishemicheskogo insul'ta sredneĭ stepeni tiazhesti. [The active neuroprotective therapy of acute carotid ischemic stroke of moderate severity]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(12):38-42. doi: 10.17116/jnevro201411412238-42. Russian. PMID: 25726801.
Copy Download .nbib Format: NLM
Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy.

EJNMMI research

Rusckowski M, Wang Y, Blankenberg FG, Levashova Z, Backer MV, Backer JM.
PMID: 26780081
EJNMMI Res. 2016 Dec;6(1):4. doi: 10.1186/s13550-016-0163-1. Epub 2016 Jan 16.

BACKGROUND: scVEGF/(177)Lu is a novel radiopharmaceutical targeted by recombinant single-chain (sc) derivative of vascular endothelial growth factor (VEGF) that binds to and is internalized by vascular endothelial growth factor receptors (VEGFR). scVEGF/(177)Lu potential as adjuvant and neoadjuvant anti-angiogenic therapy...

Cite
Rusckowski M, Wang Y, Blankenberg FG, et al. Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. EJNMMI Res. 2016;6(1):4doi: 10.1186/s13550-016-0163-1.
Rusckowski, M., Wang, Y., Blankenberg, F. G., Levashova, Z., Backer, M. V., & Backer, J. M. (2016). Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. EJNMMI research, 6(1), 4. https://doi.org/10.1186/s13550-016-0163-1
Rusckowski, Mary, et al. "Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy." EJNMMI research vol. 6,1 (2016): 4. doi: https://doi.org/10.1186/s13550-016-0163-1
Rusckowski M, Wang Y, Blankenberg FG, Levashova Z, Backer MV, Backer JM. Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. EJNMMI Res. 2016 Dec;6(1):4. doi: 10.1186/s13550-016-0163-1. Epub 2016 Jan 16. PMID: 26780081; PMCID: PMC4715132.
Copy Download .nbib Format: NLM
CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.

American journal of translational research

Hayes GM, Cairns B, Levashova Z, Chinn L, Perez M, Theunissen JW, Liao-Chan S, Bermudez A, Flory MR, Schweighofer KJ, H van der Horst E.
PMID: 26279761
Am J Transl Res. 2015 Jun 15;7(6):1181-8. eCollection 2015.

Soft tissue sarcoma (STS) is a heterogenous tumor arising from the embryonic mesoderm represented by approximately 50 histological subtypes. Effective therapeutic intervention is lacking for recurrent, late stage and metastatic disease. CD39, a cell-surface ectonucleotidase, has previously been shown...

Cite
Hayes GM, Cairns B, Levashova Z, et al. CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma. Am J Transl Res. 2015;7(6):1181-8
Hayes, G. M., Cairns, B., Levashova, Z., Chinn, L., Perez, M., Theunissen, J. W., Liao-Chan, S., Bermudez, A., Flory, M. R., Schweighofer, K. J., & H van der Horst, E. (2015). CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma. American journal of translational research, 7(6), 1181-8.
Hayes, Gregory M, et al. "CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma." American journal of translational research vol. 7,6 (2015): 1181-8.
Hayes GM, Cairns B, Levashova Z, Chinn L, Perez M, Theunissen JW, Liao-Chan S, Bermudez A, Flory MR, Schweighofer KJ, H van der Horst E. CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma. Am J Transl Res. 2015 Jun 15;7(6):1181-8. eCollection 2015. PMID: 26279761; PMCID: PMC4532750.
Copy Download .nbib Format: NLM
[Congenital deformations and their treatment in children].

Fel'dsher i akusherka

LEVASHOVA EA.
PMID: 14802448
Feldsher Akush. 1951 Jan;1:23-8.

No abstract available.

Cite
LEVASHOVA EA. Vrozhdennye deformatsii i ikh lechenie v mladencheskom vozraste. [Congenital deformations and their treatment in children]. Feldsher Akush. 1951;1:23-8
LEVASHOVA, E. A. (1951). Vrozhdennye deformatsii i ikh lechenie v mladencheskom vozraste. [Congenital deformations and their treatment in children]. Fel'dsher i akusherka, 123-8.
LEVASHOVA, E A. "Vrozhdennye deformatsii i ikh lechenie v mladencheskom vozraste." [Congenital deformations and their treatment in children]. Fel'dsher i akusherka vol. 1 (1951): 23-8.
LEVASHOVA EA. Vrozhdennye deformatsii i ikh lechenie v mladencheskom vozraste. [Congenital deformations and their treatment in children]. Feldsher Akush. 1951 Jan;1:23-8. Undetermined. PMID: 14802448.
Copy Download .nbib Format: NLM
Investigation of the Peripheral Analgesic Activity of Oxicams and Their Combinations with Caffeine.

Turkish journal of pharmaceutical sciences

Syrova A, Lukyanova L, Kozub S, Zavada O, Levashova O, Shaposhnik V.
PMID: 32939136
Turk J Pharm Sci. 2020 Aug;17(4):408-411. doi: 10.4274/tjps.galenos.2019.92063. Epub 2020 Aug 28.

OBJECTIVES: Therapy of pain syndromes involves exposure to its source, receptors, and peripheral fibers. Treatment of acute pain and inflammation involves the use of nonsteroidal anti-inflammatory drugs and nonnarcotic analgesics. An alternative to obsolete analgesics is combined compositions. Experimental...

Cite
Syrova A, Lukyanova L, Kozub S, et al. Investigation of the Peripheral Analgesic Activity of Oxicams and Their Combinations with Caffeine. Turk J Pharm Sci. 2020;17(4):408-411doi: 10.4274/tjps.galenos.2019.92063.
Syrova, A., Lukyanova, L., Kozub, S., Zavada, O., Levashova, O., & Shaposhnik, V. (2020). Investigation of the Peripheral Analgesic Activity of Oxicams and Their Combinations with Caffeine. Turkish journal of pharmaceutical sciences, 17(4), 408-411. https://doi.org/10.4274/tjps.galenos.2019.92063
Syrova, Anna, et al. "Investigation of the Peripheral Analgesic Activity of Oxicams and Their Combinations with Caffeine." Turkish journal of pharmaceutical sciences vol. 17,4 (2020): 408-411. doi: https://doi.org/10.4274/tjps.galenos.2019.92063
Syrova A, Lukyanova L, Kozub S, Zavada O, Levashova O, Shaposhnik V. Investigation of the Peripheral Analgesic Activity of Oxicams and Their Combinations with Caffeine. Turk J Pharm Sci. 2020 Aug;17(4):408-411. doi: 10.4274/tjps.galenos.2019.92063. Epub 2020 Aug 28. PMID: 32939136; PMCID: PMC7489353.
Copy Download .nbib Format: NLM
Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study.

Translational oncology

Blankenberg FG, Levashova Z, Sarkar SK, Pizzonia J, Backer MV, Backer JM.
PMID: 20165696
Transl Oncol. 2010 Feb;3(1):56-64. doi: 10.1593/tlo.09271.

Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) drive angiogenesis, and several VEGFR inhibitors are already approved for use as single agents or in combination with chemotherapy. Although there is a clear benefit with these drugs in a...

Cite
Blankenberg FG, Levashova Z, Sarkar SK, et al. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol. 2010;3(1):56-64doi: 10.1593/tlo.09271.
Blankenberg, F. G., Levashova, Z., Sarkar, S. K., Pizzonia, J., Backer, M. V., & Backer, J. M. (2010). Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Translational oncology, 3(1), 56-64. https://doi.org/10.1593/tlo.09271
Blankenberg, Francis G, et al. "Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study." Translational oncology vol. 3,1 (2010): 56-64. doi: https://doi.org/10.1593/tlo.09271
Blankenberg FG, Levashova Z, Sarkar SK, Pizzonia J, Backer MV, Backer JM. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol. 2010 Feb;3(1):56-64. doi: 10.1593/tlo.09271. PMID: 20165696; PMCID: PMC2822454.
Copy Download .nbib Format: NLM
Fabrication and use of a nanoscale Hall probe for measurements of the magnetic field induced by MFM tips.

Nanotechnology

Matveev VN, Levashov VI, Volkov VT, Kononenko OV, Chernyh AV, Knjazev MA, Tulin VA.
PMID: 21836273
Nanotechnology. 2008 Nov 26;19(47):475502. doi: 10.1088/0957-4484/19/47/475502. Epub 2008 Oct 29.

Extraordinary Hall effect probes with 160 nm × 160 nm working area were fabricated using photo- and electron-beam lithographic procedures with the aim of direct measurements of MFM cantilever tip magnetic properties. The magnetic field sensitivity of the probes...

Cite
Matveev VN, Levashov VI, Volkov VT, et al. Fabrication and use of a nanoscale Hall probe for measurements of the magnetic field induced by MFM tips. Nanotechnology. 2008;19(47):475502doi: 10.1088/0957-4484/19/47/475502.
Matveev, V. N., Levashov, V. I., Volkov, V. T., Kononenko, O. V., Chernyh, A. V., Knjazev, M. A., & Tulin, V. A. (2008). Fabrication and use of a nanoscale Hall probe for measurements of the magnetic field induced by MFM tips. Nanotechnology, 19(47), 475502. https://doi.org/10.1088/0957-4484/19/47/475502
Matveev, Victor N, et al. "Fabrication and use of a nanoscale Hall probe for measurements of the magnetic field induced by MFM tips." Nanotechnology vol. 19,47 (2008): 475502. doi: https://doi.org/10.1088/0957-4484/19/47/475502
Matveev VN, Levashov VI, Volkov VT, Kononenko OV, Chernyh AV, Knjazev MA, Tulin VA. Fabrication and use of a nanoscale Hall probe for measurements of the magnetic field induced by MFM tips. Nanotechnology. 2008 Nov 26;19(47):475502. doi: 10.1088/0957-4484/19/47/475502. Epub 2008 Oct 29. PMID: 21836273.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries